Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin
Version of Record online: 8 FEB 2012
© 2012 Blackwell Publishing Ltd
Diabetes, Obesity and Metabolism
Volume 14, Issue 6, pages 539–545, June 2012
How to Cite
Devineni, D., Morrow, L., Hompesch, M., Skee, D., Vandebosch, A., Murphy, J., Ways, K. and Schwartz, S. (2012), Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes, Obesity and Metabolism, 14: 539–545. doi: 10.1111/j.1463-1326.2012.01558.x
- Issue online: 22 APR 2012
- Version of Record online: 8 FEB 2012
- Accepted manuscript online: 6 JAN 2012 03:16PM EST
- Date submitted 26 July 2011; date of first decision 6 September 2011; date of final acceptance 23 December 2011
- 1JNJ-28431754/TA-7284, an SGLT inhibitor, lowers blood glucose and reduces body weight in obese and type 2 diabetic animal models, New Orleans, LA, Poster presented at the American Diabetes Association 69th Scientific Session, June 5–9, 2009., , et al.
- 2Effect of canagliflozin on renal threshold for glucose excretion in diabetic animals, San Diego, CA, Poster presented at the American Diabetes Association 71st Scientific Session, June 24–28, 2011., , et al.
- 3Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011; 13: 669–672., , et al.
- 4Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, improved glucose control in subjects with type 2 diabetes and was well tolerated (Abstract #568-P). American Diabetes Association, 70th Scientific Sessions, 2010; Orlando, FL., , et al.